MS is a complex, heterogeneous, chronic disease that requires individualized treatment throughout a patient’s life. The disease involves the central nervous system and disrupts the flow of information within the brain and between the brain and body, signaling unpredictable symptoms.1
Over the past four decades, Biogen has been committed to translating science to meaningful advances for the MS community. Our industry-leading portfolio — backed by established safety and efficacy profiles, ongoing investment in our products, as well as our comprehensive services and solutions — enables us to offer a broad range of options to meet the ever-evolving needs of MS patients and drive greater individualized disease management.
As MS disease management and patient needs evolve, Biogen remains focused on novel research initiatives and technological innovations to further the understanding of MS and improve patient outcomes. While we focus on advancing current assets in our pipeline, we aspire to pioneer disruptive therapies for MS prevention and cure through exploration in emerging science, including novel treatment approaches such as vaccine cell-based therapies, new mechanisms of remyelination and neuroprotection, and developing additional preclinical models that have enhanced translational predictability.
Complementing our innovative research initiatives, Biogen Canada is a founding and proud funding partner of the $11.5+ million Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo). The initiative brings together nearly 50 leading MS researchers from various scientific disciplines across Canada – which has one of the highest rates of MS in the world2 – to better understand and treat MS progression by connecting biological, real world and clinical findings.
Diagnosed with MS soon after her 25th birthday, Tracy was terrified that this diagnosis would rob her of the things she loved to do, like running and being active. Today, 15 years later, she is a busy mom of 2-year-old Riley, and executive assistant to an executive officer at Biogen. She talks about her inner strength and determination to overcome her diagnosis.
Canadians3 and 2.8 million people worldwide4 live with MS.
Canadians5 and 1.9 million people globally have been treated with a Biogen therapy.5
We have led in the research and development of new therapies to treat MS.
A one-stop shop mobile app for all questions MS. The app offers tailored information about life with MS and provides patients with access to healthcare professionals who can answer frequently asked questions.
Available for patients whom have been prescribed a Biogen MS therapy or Biogen biosimilar. The Biogen One™ patient support program is designed to simplify and ease the MS treatment experience by providing a range of services, from patient education, injection training/infusion services and blood monitoring, to reimbursement and financial assistance, side effect monitoring and management.
A website dedicated to helping patients take charge of their MS by helping them better understand the disease and how it's diagnosed, treated and managed. It provides answers to common questions about the disease and offers links to useful resources so patients can get the support they need, wherever they are in their MS journey.